Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

Source Summary

July 8 () - Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday ‌its China unit had secured ‌rights to market two respiratory drugs from British company ​GSK in mainland China. Here are some details: • Chia Tai Tianqing Pharmaceutical (CTTQ) will commercialise GSK's triple therapy inhaler Trelegy ‌Ellipta and ⁠dual therapy inhaler Anoro Ellipta in mainland China.